# Roderick L Beijersbergen

List of Publications by Year
in descending order



| 88 | 18,148 | 53660 45 | 51492 86 |
|---|---|---|---|
| papers | citations | h-index | g-index |

| 97 | 97 | 97 | 23873 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Creation of human tumour cells with defined genetic elements. Nature, 1999, 400, 464-468. | 13.7 | 2,148 |
| 2 | Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature, 2012, 483, 100-103. | 13.7 | 1,769 |
| 3 | hEST2, the Putative Human Telomerase Catalytic Subunit Gene, Is Up-Regulated in Tumor Cells and during Immortalization. Cell, 1997, 90, 785-795. | 13.5 | 1,689 |
| 4 | A Functional Genetic Approach Identifies the PI3K Pathway as a Major Determinant of Trastuzumab Resistance in Breast Cancer. Cancer Cell, 2007, 12, 395-402. | 7.7 | 1,471 |
| 5 | Inhibition of telomerase limits the growth of human cancer cells. Nature Medicine, 1999, 5, 1164-1170. | 15.2 | 983 |
| 6 | A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature, 2004, 428, 431-437. | 13.7 | 955 |
| 7 | Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature, 2014, 508, 118-122. | 13.7 | 702 |
| 8 | Dissociation among in vitro telomerase activity, telomere maintenance, and cellular immortalization. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 14723-14728. | 3.3 | 582 |
| 9 | Statistical methods for analysis of high-throughput RNA interference screens. Nature Methods, 2009, 6, 569-575. | 9.0 | 532 |
| 10 | Phosphatidylinositol 3-Kinase Hyperactivation Results in Lapatinib Resistance that Is Reversed by the mTOR/Phosphatidylinositol 3-Kinase Inhibitor NVP-BEZ235. Cancer Research, 2008, 68, 9221-9230. | 0.4 | 474 |
| 11 | Stabilization of N-Myc Is a Critical Function of Aurora A in Human Neuroblastoma. Cancer Cell, 2009, 15, 67-78. | 7.7 | 464 |
| 12 | The ubiquitin-specific protease USP28 is required for MYC stability. Nature Cell Biology, 2007, 9, 765-774. | 4.6 | 391 |
| 13 | MED12 Controls the Response to Multiple Cancer Drugs through Regulation of TGF-Î² Receptor Signaling. Cell, 2012, 151, 937-950. | 13.5 | 371 |
| 14 | CRISPR knockout screening outperforms shRNA and CRISPRi in identifying essential genes. Nature Biotechnology, 2016, 34, 631-633. | 9.4 | 344 |
| 15 | E2F-4, a new member of the E2F gene family, has oncogenic activity and associates with p107 in vivo.. Genes and Development, 1994, 8, 2680-2690. | 2.7 | 312 |
| 16 | Intracellular bacterial growth is controlled by a kinase network around PKB/AKT1. Nature, 2007, 450, 725-730. | 13.7 | 310 |
| 17 | Intrinsic Resistance to MEK Inhibition in KRAS Mutant Lung and Colon Cancer through Transcriptional Induction of ERBB3. Cell Reports, 2014, 7, 86-93. | 2.9 | 266 |
| 18 | A Genetic Screen Identifies PITX1 as a Suppressor of RAS Activity and Tumorigenicity. Cell, 2005, 121, 849-858. | 13.5 | 257 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Inducing and exploiting vulnerabilities for the treatment of liver cancer. Nature, 2019, 574, 268-272. | 13.7 | 249 |
| 20 | Neutrophils Kill Antibody-Opsonized Cancer Cells by Trogoptosis. Cell Reports, 2018, 23, 3946-3959.e6. | 2.9 | 245 |
| 21 | E2F-5, a New E2F Family Member That Interacts with p130 In Vivo. Molecular and Cellular Biology, 1995, 15, 3082-3089. | 1.1 | 228 |
| 22 | An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors. Nature Chemical Biology, 2006, 2, 202-206. | 3.9 | 196 |
| 23 | EGFR activation limits the response of liver cancer to lenvatinib. Nature, 2021, 595, 730-734. | 13.7 | 183 |
| 24 | PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs. Cell Reports, 2015, 12, 1978-1985. | 2.9 | 163 |
| 25 | A Genome-wide Multidimensional RNAi Screen Reveals Pathways Controlling MHC Class II Antigen Presentation. Cell, 2011, 145, 268-283. | 13.5 | 151 |
| 26 | High-Throughput Functional Genetic and Compound Screens Identify Targets for Senescence Induction in Cancer. Cell Reports, 2017, 21, 773-783. | 2.9 | 136 |
| 27 | ZNF423 Is Critically Required for Retinoic Acid-Induced Differentiation and Is a Marker of Neuroblastoma Outcome. Cancer Cell, 2009, 15, 328-340. | 7.7 | 132 |
| 28 | Cloning, expression and chromosomal localization of a new putative receptor-like protein tyrosine phosphatase. FEBS Letters, 1991, 290, 123-130. | 1.3 | 125 |
| 29 | Advances in CRISPR-Cas9 genome engineering: lessons learned from RNA interference. Nucleic Acids Research, 2015, 43, 3407-3419. | 6.5 | 124 |
| 30 | A Large Scale shRNA Barcode Screen Identifies the Circadian Clock Component ARNTL as Putative Regulator of the p53 Tumor Suppressor Pathway. PLoS ONE, 2009, 4, e4798. | 1.1 | 118 |
| 31 | shRNA libraries and their use in cancer genetics. Nature Methods, 2006, 3, 701-706. | 9.0 | 116 |
| 32 | Impact of chromatin context on Cas9-induced DNA double-strand break repair pathway balance. Molecular Cell, 2021, 81, 2216-2230.e10. | 4.5 | 106 |
| 33 | Involvement of MINK, a Ste20 Family Kinase, in Ras Oncogene-Induced Growth Arrest in Human Ovarian Surface Epithelial Cells. Molecular Cell, 2005, 20, 673-685. | 4.5 | 96 |
| 34 | Cell cycle regulation by the retinoblastoma family of growth inhibitory proteins. Biochimica Et Biophysica Acta: Reviews on Cancer, 1996, 1287, 103-120. | 3.3 | 94 |
| 35 | The Cancer SENESCopedia: A delineation of cancer cell senescence. Cell Reports, 2021, 36, 109441. | 2.9 | 84 |
| 36 | Loss of p53 induces cell proliferation via Ras-independent activation of the Raf/Mek/Erk signaling pathway. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 15155-15160. | 3.3 | 80 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Phospho-ERK is a biomarker of response to a synthetic lethal drug combination of sorafenib and MEK inhibition in liver cancer. Journal of Hepatology, 2018, 69, 1057-1065. | 1.8 | 74 |
| 38 | CDK12 inhibition mediates DNA damage and is synergistic with sorafenib treatment in hepatocellular carcinoma. Gut, 2020, 69, 727-736. | 6.1 | 74 |
| 39 | ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors. Oncogene, 2018, 37, 4611-4625. | 2.6 | 72 |
| 40 | Miz1 and HectH9 regulate the stability of the checkpoint protein, TopBP1. EMBO Journal, 2008, 27, 2851-2861. | 3.5 | 70 |
| 41 | A Vulnerability of a Subset of Colon Cancers with Potential Clinical Utility. Cell, 2016, 165, 317-330. | 13.5 | 70 |
| 42 | Telomerase-independent Regulation of ATR by Human Telomerase RNA. Journal of Biological Chemistry, 2006, 281, 40503-40514. | 1.6 | 66 |
| 43 | Effects of Monomethylfumarate on Human Granulocytes. Journal of Investigative Dermatology, 1993, 101, 37-42. | 0.3 | 59 |
| 44 | A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma. European Urology, 2017, 71, 858-862. | 0.9 | 59 |
| 45 | An integrated genomic approach identifies that the PI3K/AKT/FOXO pathway is involved in breast cancer tumor initiation. Oncotarget, 2016, 7, 2596-2610. | 0.8 | 52 |
| 46 | A CRISPR screen identifies CDK7 as a therapeutic target in hepatocellular carcinoma. Cell Research, 2018, 28, 690-692. | 5.7 | 46 |
| 47 | Inhibition of Ataxia-Telangiectasia Mutated and RAD3-Related (ATR) Overcomes Oxaliplatin Resistance and Promotes Antitumor Immunity in Colorectal Cancer. Cancer Research, 2019, 79, 2933-2946. | 0.4 | 46 |
| 48 | The Histone Demethylase Jarid1b (Kdm5b) Is a Novel Component of the Rb Pathway and Associates with E2f-Target Genes in MEFs during Senescence. PLoS ONE, 2011, 6, e25235. | 1.1 | 44 |
| 49 | Loss of ARID1A Activates ANXA1, which Serves as a Predictive Biomarker for Trastuzumab Resistance. Clinical Cancer Research, 2016, 22, 5238-5248. | 3.2 | 43 |
| 50 | EGFR overexpression induces activation of telomerase via PI3K/AKTâ€mediated phosphorylation and transcriptional regulation through Hif1â€alpha in a cellular model of oralâ€“esophageal carcinogenesis. Cancer Science, 2011, 102, 351-360. | 1.7 | 42 |
| 51 | Functional Analysis of Burkitt's Lymphoma Mutant c-Myc Proteins. Journal of Biological Chemistry, 1996, 271, 5513-5518. | 1.6 | 39 |
| 52 | Identification of <scp>F</scp>â€box only protein 7 as a negative regulator of <scp>NF</scp>â€kappa<scp>B</scp> signalling. Journal of Cellular and Molecular Medicine, 2012, 16, 2140-2149. | 1.6 | 38 |
| 53 | Identification of signalling cascades involved in red blood cell shrinkage and vesiculation. Bioscience Reports, 2015, 35, . | 1.1 | 37 |
| 54 | SMARCE1 suppresses EGFR expression and controls responses to MET and ALK inhibitors in lung cancer. Cell Research, 2015, 25, 445-458. | 5.7 | 36 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Synthetic Lethality in Cancer Therapeutics. Annual Review of Cancer Biology, 2017, 1, 141-161. | 2.3 | 36 |
| 56 | Glucocorticoid receptor triggers a reversible drug-tolerant dormancy state with acquired therapeutic vulnerabilities in lung cancer. Nature Communications, 2021, 12, 4360. | 5.8 | 35 |
| 57 | Parallel InÂVivo and InÂVitro Melanoma RNAi Dropout Screens Reveal Synthetic Lethality between Hypoxia and DNA Damage Response Inhibition. Cell Reports, 2014, 9, 1375-1386. | 2.9 | 34 |
| 58 | Sensitizing Triple-Negative Breast Cancer to PI3K Inhibition by Cotargeting IGF1R. Molecular Cancer Therapeutics, 2016, 15, 1545-1556. | 1.9 | 30 |
| 59 | Ezh2 inhibition in Kras-driven lung cancer amplifies inflammation and associated vulnerabilities. Journal of Experimental Medicine, 2018, 215, 3115-3135. | 4.2 | 29 |
| 60 | VAV3 mediates resistance to breast cancer endocrine therapy. Breast Cancer Research, 2014, 16, R53. | 2.2 | 28 |
| 61 | PIM Kinases Are a Potential Prognostic Biomarker and Therapeutic Target in Neuroblastoma. Molecular Cancer Therapeutics, 2018, 17, 849-857. | 1.9 | 28 |
| 62 | A role for the unfolded protein response stress sensor ERN1 in regulating the response to MEK inhibitors in KRAS mutant colon cancers. Genome Medicine, 2018, 10, 90. | 3.6 | 28 |
| 63 | The Corepressor CTBP2 Is a Coactivator of Retinoic Acid Receptor/Retinoid X Receptor in Retinoic Acid Signaling. Molecular and Cellular Biology, 2013, 33, 3343-3353. | 1.1 | 25 |
| 64 | The lethal response to Cdk1 inhibition depends on sister chromatid alignment errors generated by KIF4 and isoform 1 of PRC1. Scientific Reports, 2015, 5, 14798. | 1.6 | 25 |
| 65 | TLE3 loss confers AR inhibitor resistance by facilitating GR-mediated human prostate cancer cell growth. ELife, 2019, 8, . | 2.8 | 25 |
| 66 | A genome-wide RNAi screen in mouse embryonic stem cells identifies Mp1 as a key mediator of differentiation. Journal of Experimental Medicine, 2011, 208, 2675-2689. | 4.2 | 24 |
| 67 | Targeting CDC7 potentiates ATR-CHK1 signaling inhibition through induction of DNA replication stress in liver cancer. Genome Medicine, 2021, 13, 166. | 3.6 | 19 |
| 68 | Differential transcriptional regulation of human telomerase in a cellular model representing important genetic alterations in esophageal squamous carcinogenesis. Carcinogenesis, 2005, 26, 1879-1889. | 1.3 | 16 |
| 69 | Intrinsic resistance to PIM kinase inhibition in AML through p38Î±-mediated feedback activation of mTOR signaling. Oncotarget, 2016, 7, 37407-37419. | 0.8 | 16 |
| 70 | Screening for modulators of cisplatin sensitivity: Unbiased screens reveal common themes. Cell Cycle, 2011, 10, 380-386. | 1.3 | 15 |
| 71 | Exploration of synthetic lethal interactions as cancer drug targets. Future Oncology, 2010, 6, 1789-1802. | 1.1 | 14 |
| 72 | Integrative Modeling Identifies Key Determinants of Inhibitor Sensitivity in Breast Cancer Cell Lines. Cancer Research, 2018, 78, 4396-4410. | 0.4 | 14 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Highâ€throughput compound screen reveals mTOR inhibitors as potential therapeutics to reduce (auto)antibody production by human plasma cells. European Journal of Immunology, 2020, 50, 73-85. | 1.6 | 12 |
| 74 | Old drugs with new tricks. Nature Cancer, 2020, 1, 153-155. | 5.7 | 10 |
| 75 | Integrated in vivo genetic and pharmacologic screening identifies co-inhibition of EGRF and ROCK as a potential treatment regimen for triple-negative breast cancer. Oncotarget, 2016, 7, 42859-42872. | 0.8 | 10 |
| 76 | Candidate Biomarkers of Response to an Experimental Cancer Drug Identified through a Large-scale RNA Interference Genetic Screen. Clinical Cancer Research, 2009, 15, 5811-5819. | 3.2 | 9 |
| 77 | A kinome-centered CRISPR-Cas9 screen identifies activated BRAF to modulate enzalutamide resistance with potential therapeutic implications in BRAF-mutated prostate cancer. Scientific Reports, 2021, 11, 13683. | 1.6 | 8 |
| 78 | Pooled shRNA Screening in Mammalian Cells as a Functional Genomic Discovery Platform. Methods in Molecular Biology, 2016, 1470, 49-73. | 0.4 | 6 |
| 79 | Identification of Autophagy-Related Genes as Targets for Senescence Induction Using a Customizable CRISPR-Based Suicide Switch Screen. Molecular Cancer Research, 2021, 19, 1613-1621. | 1.5 | 6 |
| 80 | Genetic and compound screens uncover factors modulating cancer cell response to indisulam. Life Science Alliance, 2022, 5, e202101348. | 1.3 | 6 |
| 81 | Using large-scale RNAi screens to identify novel drug targets for cancer. IDrugs: the Investigational Drugs Journal, 2010, 13, 772-7. | 0.7 | 5 |
| 82 | A loss-of-adhesion CRISPR-Cas9 screening platform to identify cell adhesion-regulatory proteins and signaling pathways. Nature Communications, 2022, 13, 2136. | 5.8 | 4 |
| 83 | Interleukin-1Râ€“Associated Kinase 2 Is a Novel Modulator of the Transforming Growth Factor Î² Signaling Cascade. Molecular Cancer Research, 2010, 8, 592-603. | 1.5 | 3 |
| 84 | Ribociclib Induces Broad Chemotherapy Resistance and EGFR Dependency in ESR1 Wildtype and Mutant Breast Cancer. Cancers, 2021, 13, 6314. | 1.7 | 3 |
| 85 | The Good, the Bad, and the Ugly: in search of gold standards for assessing functional genetic screen quality. Molecular Systems Biology, 2014, 10, 738. | 3.2 | 2 |
| 86 | It takes two to tango, and the right music: Synergistic drug combinations with cell-cycle phase-dependent sensitivities. EBioMedicine, 2021, 69, 103448. | 2.7 | 1 |
| 87 | Bioassay development. , 0, , 67-84. | | 0 |
| 88 | Functional Subtyping of Breast Cancer. Cancer Discovery, 2011, 1, 205-206. | 7.7 | 0 |